Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1385 participants.

Also called NCT04518293

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,385 participants (enrolled count) (from the registry)
Sponsor
George Medicines PTY Limited (from the registry)
Registry
  • NCT NCT04518293
Other papers using this trial's data
  • Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial Lancet (London, England), 2024-10-19 DOI, PubMed 39426836

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Czechia, New Zealand, Poland, Sri Lanka, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04518293. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-09 (actual); primary completion 2023-08-11 (actual). Results posted on 2025-06-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension
Acronym
GMRx2_ACT
Condition
Hypertension
Intervention (Drug)
Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
Intervention (Drug)
telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
Intervention (Drug)
Telmisartan 20 mg/amlodipine 2.5 mg
Intervention (Drug)
telmisartan 40 mg/amlodipine 5 mg
Intervention (Drug)
Telmisartan 20 mg/indapamide 1.25 mg
Intervention (Drug)
telmisartan 40 mg/indapamide 2.5 mg
Intervention (Drug)
Amlodipine 2.5 mg/indapamide 1.25 mg
Intervention (Drug)
amlodipine 5 mg/indapamide 2.5 mg
Lead sponsor
George Medicines PTY Limited (class: industry)

Record details

Record id
cardio:ct-nct04518293
Content hash
0513b47ea4b70389daf379fdb4a63ebef536ca91396e57b70f81f40a50c0388d